Eurocine Vaccines has started a Phase 1/2 clinical study of its Immunose FLU intranasal quadrivalent influenza vaccine, which uses the company’s Endocine adjuvent and inactivated split antigens, the company said. Results should be available in mid-2017.
Eurocine Vaccines Chief Scientific Officer Anna-Karin Maltais said, “We are very pleased that our nasal influenza vaccine candidate, Immunose FLU has entered the clinical development stage. This is the first step on the path to create a better, more effective influenza vaccine for children.”
CEO Hans Arwidsson commented, “I am impressed by the commitment and diligence showed by both our internal team and our team of contract research organizations.”
Read the Eurocine Vaccines press release.
